• Tekedia Capital disclosed an investment in Anto Biosciences in a private financing round.
• Anto develops AI foundation models for microbial communities to make the gut microbiome computable for drug development.
• Its Darwin model series targets prediction of drug toxicity and efficacy across populations to support molecule optimization.
• Anto uses quality-aware, goal-directed sparsification to filter microbiome data, aiming to isolate biologically meaningful signals.
• The company was founded by Arvid, formerly at the Broad Institute, and David, from Harvard Medical School Gastroenterology and Johnson & Johnson.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tekedia Capital LLC published the original content used to generate this news brief on June 13, 2026, and is solely responsible for the information contained therein.